Gilead Sciences has strengthened its lines with newly appointed Hematology and Oncology Therapeutic Area Head, who came from Novartis.
The new guy is Alessandro Riva, MD, and he will serve in Gilead as Senior Vice President and will report to John McHutchison, MD, Executive Vice President, Clinical Research and will have responsibility for Gilead’s hematology and oncology programs. Dr Riva will also join Gilead’s Executive Committee, the company said on Tuesday.
Alessandro Riva, M.D.
Dr. Riva joins Gilead from Novartis Oncology, where he served as Head, Global Oncology Development.
During his career, Alessandro has authored or co-authored more than 100 oncology research manuscripts and abstracts. He is a member of the American Society of Clinical Oncology and the European Society for Medical Oncology.
“I am thrilled to welcome Alessandro, who brings a wealth of experience and expertise in hematology/oncology drug development and translational medicine,” said Dr. McHutchison. “His leadership and proven track record developing therapies across the spectrum of hematological malignancies and solid tumors will be instrumental as we continue to grow and advance our pipeline of novel therapeutics for people living with cancer.”
“I have always admired Gilead for its scientific focus and data-driven approach to drug development,” said Dr. Riva. “I look forward to working alongside Gilead’s dedicated and passionate colleagues throughout the R&D organization to tackle the cancer research and development challenge with a goal of improving the lives of patients.”